Publications

Members of the Metabolic Continuum Roundtable™ contribute important research to the public domain through peer-reviewed articles in medical journals. Below is a selection of recent research co-authored by Roundtable contributors. For a comprehensive search of metabolic-related research by Roundtable contributors and others, visit pubmed.gov.

Filter

July 2024

MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials.

Zannad F, Sanyal AJ, Butler J, Ferreira JP, Girerd N, Miller V, Pandey A, Parikh CR, Ratziu V, Younossi ZM, Harrison SA. J Intern Med. 2024 Jul;296(1):24-38. doi: 10.1111/joim.13793.

Publications

Filter

MASLD and MASH at the crossroads of hepatology trials and cardiorenal metabolic trials.

Is digital pathology the new standard in MASH trials?

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).

The fibroblast hormone endotrophin is a biomarker of mortality in chronic diseases.

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.

A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.

Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.

Envisioning how to advance the MASH field.

The impact of genetic risk on the prevalence of advanced fibrosis and cirrhosis in prospectively assessed patients with type 2 diabetes.

Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis – prevalence, clinical impact, economic implications and management strategies.

Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity.

LiverAI: New tool in the landscape for liver health.

New and emerging treatments for metabolic dysfunction-associated steatohepatitis.

A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.

A prospective study on the prevalence of at-risk MASH in patients with type 2 diabetes mellitus in the United States.

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction-associated steatotic liver disease.

Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.

Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease.

The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.

Changing from NAFLD to MASLD: The implications for health-related quality of life data.

Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept study.

The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD).

Integrating genetic and socioeconomic data to predict the progression of nonalcoholic fatty liver disease.

Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.

Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?

Increases and decreases in liver stiffness measurements are independently associated with the risk of liver-related events in NAFLD.

The new hepatic steatosis nomenclature. No more NAFLD!

Liver histology is associated with long-term clinical outcomes in patients with metabolic dysfunction-associated steatohepatitis.

High Concordance Between Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease in the TARGET-NASH Real-World Cohort.

Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis.

Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome.

Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease.

Health-related quality of life in non-alcoholic fatty liver disease: A cross-cultural study between Spain and the United Kingdom.

Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.

BCG Vaccination-Associated Lower HbA1c and Increased CD25 Expression on CD8+ T Cells in Patients with Type 1 Diabetes in Ghana.

Cost-effectiveness of diagnosis and treatment of early gestational diabetes mellitus: economic evaluation of the TOBOGM study, an international multicenter randomized controlled trial.

PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease.

Use of non-invasive diagnostic tools for metabolic dysfunction-associated steatohepatitis: A qualitative exploration of challenges and barriers.

The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease.

The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.

Potential Therapeutic Targets in Obesity, Sleep Apnea, Diabetes, and Fatty Liver Disease.

Diagnostic accuracy of non-invasive tests to screen for at-risk MASH-An individual participant data meta-analysis.

Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction.

Metabolic dysfunction-associated steatohepatitis (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) require urgent attention by primary care physicians and endocrinologists.

Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting.

Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.

Dietary and pharmacological treatment in patients with metabolic-dysfunction associated steatotic liver disease.

Emerging Combination of Saroglitazar and Vitamin E for the Treatment of NAFLD and NASH.

Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial.

Nutrition assessment and MASH severity in children using the Healthy Eating Index.

Impact of Type 2 Diabetes on the Outcomes of Solid Organ Transplantations in the U.S.: Data From a National Registry.

Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease.

The Impact and Burden of Dietary Sugars on the Liver.

A randomised Phase IIa trial of amine oxidase copper-containing 3 (AOC3) inhibitor BI 1467335 in adults with non-alcoholic steatohepatitis.

Diabetes mellitus, energy metabolism and COVID-19.

A nutrigenetic precision approach for the management of non-alcoholic fatty liver disease.

Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS).

Looking for the best algorithm in diabetes population for advanced fibrosis detection: The best is the enemy of the good.

Diagnosis and assessment of disease severity in patients with nonalcoholic fatty liver disease.

Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality.

Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.

Risk factors for fibrosis progression in non-alcoholic steatohepatitis: analysis of the European cohort in the real-world GAIN study.

Homeostasis Model Assessment of β-Cell Function for Diagnosis of Insulinoma.

Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR-MASH score.

Impact of physical fitness and exercise training on subcutaneous adipose tissue beiging markers in humans with and without diabetes and a high-fat diet-fed mouse model.

Precise glucose measurement in sodium fluoride-citrate plasma affects estimates of prevalence in diabetes and prediabetes.

Reduced Insulin Clearance Differently Relates to Increased Liver Lipid Content and Worse Glycemic Control in Recent-Onset Type 2 and Type 1 Diabetes.

A prospective, multicenter, three-cohort study evaluating contrast-induced acute kidney injury (CI-AKI) in patients with cirrhosis.

Digital pathology and artificial intelligence in non-alcoholic steatohepatitis: current status and future directions.

Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.

Long-term follow-up of web-based and group-based behavioural intervention in NAFLD in a real world clinical setting.

Inter-organ crosstalk during development and progression of type 2 diabetes mellitus.

Nutrition could prevent or promote non-alcoholic fatty liver disease: an opportunity for intervention.

Correlates of Skeletal Muscle Mass and Differences Between Novel Subtypes in Recent-onset Diabetes.

Risk of severe infection in patients with non-alcoholic fatty liver disease: Implication on clinical management.

Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions.

Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women.